-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ChromaDex Co. (NASDAQ:CDXC) Sees Large Increase in Short Interest
ChromaDex Co. (NASDAQ:CDXC) Sees Large Increase in Short Interest
ChromaDex Co. (NASDAQ:CDXC – Get Rating) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 2,260,000 shares, an increase of 5.6% from the August 15th total of 2,140,000 shares. Currently, 5.9% of the shares of the company are sold short. Based on an average trading volume of 461,600 shares, the short-interest ratio is presently 4.9 days.
Analysts Set New Price Targets
Several analysts have recently weighed in on CDXC shares. B. Riley downgraded shares of ChromaDex from a "buy" rating to a "neutral" rating and lowered their target price for the company from $6.00 to $2.40 in a report on Thursday, August 11th. HC Wainwright lowered their target price on shares of ChromaDex from $7.00 to $5.50 and set a "buy" rating on the stock in a report on Monday, August 29th. Finally, Oppenheimer cut shares of ChromaDex from an "outperform" rating to a "market perform" rating in a research note on Tuesday, August 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $5.48.
Get ChromaDex alerts:Institutional Investors Weigh In On ChromaDex
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in ChromaDex by 9.5% in the first quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company's stock valued at $6,842,000 after purchasing an additional 240,414 shares during the period. Tieton Capital Management LLC grew its holdings in ChromaDex by 59.9% in the second quarter. Tieton Capital Management LLC now owns 2,285,015 shares of the company's stock valued at $3,816,000 after purchasing an additional 856,273 shares during the period. State Street Corp grew its holdings in ChromaDex by 4.1% in the first quarter. State Street Corp now owns 932,526 shares of the company's stock valued at $2,294,000 after purchasing an additional 36,308 shares during the period. Millennium Management LLC purchased a new stake in ChromaDex in the second quarter valued at approximately $1,275,000. Finally, Renaissance Technologies LLC grew its holdings in ChromaDex by 76.0% in the second quarter. Renaissance Technologies LLC now owns 739,900 shares of the company's stock valued at $1,236,000 after purchasing an additional 319,399 shares during the period. 41.83% of the stock is currently owned by hedge funds and other institutional investors.
ChromaDex Price Performance
CDXC traded down $0.02 during midday trading on Wednesday, reaching $1.39. 200 shares of the company's stock were exchanged, compared to its average volume of 156,641. The business's 50-day moving average price is $1.64 and its 200 day moving average price is $1.90. The stock has a market capitalization of $94.99 million, a PE ratio of -3.44 and a beta of 1.74. ChromaDex has a 1-year low of $1.36 and a 1-year high of $6.98.ChromaDex (NASDAQ:CDXC – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative net margin of 41.01% and a negative return on equity of 99.51%. During the same quarter last year, the business posted ($0.08) earnings per share. As a group, analysts expect that ChromaDex will post -0.3 EPS for the current fiscal year.
About ChromaDex
(Get Rating)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- General Mills: Superior Returns With Less Volatility
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
ChromaDex Co. (NASDAQ:CDXC – Get Rating) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 2,260,000 shares, an increase of 5.6% from the August 15th total of 2,140,000 shares. Currently, 5.9% of the shares of the company are sold short. Based on an average trading volume of 461,600 shares, the short-interest ratio is presently 4.9 days.
ChromaDex Co.(纳斯达克:CDXC-GET Rating)是空头股数8月份大幅上调的目标。截至8月31日,空头股数共有226万股,比8月15日的214万股增加了5.6%。目前,该公司5.9%的股份被卖空。以46.16万股的平均成交量计算,目前短息比为4.9天。
Analysts Set New Price Targets
分析师设定新的价格目标
Several analysts have recently weighed in on CDXC shares. B. Riley downgraded shares of ChromaDex from a "buy" rating to a "neutral" rating and lowered their target price for the company from $6.00 to $2.40 in a report on Thursday, August 11th. HC Wainwright lowered their target price on shares of ChromaDex from $7.00 to $5.50 and set a "buy" rating on the stock in a report on Monday, August 29th. Finally, Oppenheimer cut shares of ChromaDex from an "outperform" rating to a "market perform" rating in a research note on Tuesday, August 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $5.48.
几位分析师最近纷纷买入CDXC的股票。B.莱利在8月11日周四的一份报告中将ChromaDex的股票评级从买入下调至中性,并将该公司的目标价从6.00美元下调至2.40美元。在8月29日周一的一份报告中,HC Wainwright将ChromaDex的股票目标价从7.00美元下调至5.50美元,并将该股的评级定为“买入”。最后,在8月16日星期二的一份研究报告中,奥本海默将ChromaDex的股票评级从“跑赢大盘”下调至“市场表现”。三位研究分析师对该股的评级为持有,两位分析师对该公司股票的评级为买入。根据MarketBeat,该公司平均评级为持有,平均目标价为5.48美元。
Institutional Investors Weigh In On ChromaDex
机构投资者买入ChromaDex
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in ChromaDex by 9.5% in the first quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company's stock valued at $6,842,000 after purchasing an additional 240,414 shares during the period. Tieton Capital Management LLC grew its holdings in ChromaDex by 59.9% in the second quarter. Tieton Capital Management LLC now owns 2,285,015 shares of the company's stock valued at $3,816,000 after purchasing an additional 856,273 shares during the period. State Street Corp grew its holdings in ChromaDex by 4.1% in the first quarter. State Street Corp now owns 932,526 shares of the company's stock valued at $2,294,000 after purchasing an additional 36,308 shares during the period. Millennium Management LLC purchased a new stake in ChromaDex in the second quarter valued at approximately $1,275,000. Finally, Renaissance Technologies LLC grew its holdings in ChromaDex by 76.0% in the second quarter. Renaissance Technologies LLC now owns 739,900 shares of the company's stock valued at $1,236,000 after purchasing an additional 319,399 shares during the period. 41.83% of the stock is currently owned by hedge funds and other institutional investors.
一些机构投资者最近买卖了该股的股票。先锋集团第一季度增持ChromaDex 9.5%的股份。先锋集团目前持有该公司2,781,437股股票,价值6,842,000美元,在此期间又购买了240,414股。Tieton Capital Management LLC在第二季度增持了59.9%的ChromaDex股份。Tieton Capital Management LLC在此期间额外购买了856,273股,目前拥有2,285,015股该公司股票,价值3,816,000美元。道富集团第一季度持有的ChromaDex股份增加了4.1%。道富银行目前持有该公司932,526股股票,价值2,294,000美元,在此期间又购买了36,308股。Millennium Management LLC在第二季度购买了ChromaDex的新股份,价值约1,275,000美元。最后,复兴科技有限责任公司在第二季度增持了76.0%的ChromaDex。复兴科技有限责任公司在此期间又购买了319,399股,现在拥有739,900股该公司的股票,价值1,236,000美元。41.83%的股票目前由对冲基金和其他机构投资者持有。
ChromaDex Price Performance
ChromaDex性价比
ChromaDex (NASDAQ:CDXC – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative net margin of 41.01% and a negative return on equity of 99.51%. During the same quarter last year, the business posted ($0.08) earnings per share. As a group, analysts expect that ChromaDex will post -0.3 EPS for the current fiscal year.
ChromaDex(纳斯达克代码:CDXC-GET Rating)上一次公布季度收益数据是在8月10日星期三。该公司公布本季度每股收益为0.09美元,低于分析师普遍预期的0.08美元和0.01美元。ChromaDex的净利润率为负41.01%,股本回报率为负99.51%。去年同一季度,该业务公布的每股收益为0.08美元。作为一个整体,分析师预计ChromaDex本财年的每股收益将达到0.3欧元。
About ChromaDex
关于ChromaDex
(Get Rating)
(获取评级)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex公司是一家专注于健康老龄化的生物科学公司。该公司通过三个部门运营:消费品;配料;以及分析参考标准和服务。它研究烟酰胺腺嘌呤二核苷酸(NAD+);直接向消费者和经销商提供含有其专利成分的成品膳食补充剂产品;开发基于专利的成分技术并将其商业化,并将这些成分作为原材料供应给消费品制造商。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- General Mills: Superior Returns With Less Volatility
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- 免费获取StockNews.com在ChromaDex(CDXC)上的研究报告
- 连续60年提高股息的3只防御性股票
- 通用磨坊:波动性更小、回报更高
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但并未出局
- 如果你渴望价值,那就尝尝露丝的好客之道吧
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChromaDex Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ChromaDex和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧